Robert A. Anders
Johns Hopkins University · 752 works · 76,436 citations · h-index 99
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP
- PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
- The Merlin/NF2 Tumor Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in Mammals
- Expression of Yes-associated protein in common solid tumors
- Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems